Phase III trials of drug for Bekhterev's disease are nearing completion

The new drug was manufactured by Biocad

A new drug for the treatment of Bekhterev's disease is successfully undergoing the third phase of clinical trials. This was announced by the director of the Nasonova Research Institute of Rheumatology, Corresponding Member of the Russian Academy of Sciences Alexander Lila.

Such a drug was developed by the domestic company «Biocad» and has been undergoing clinical trials for several years. Today, we are completing the second phase, the third phase is underway, and in these two phases, more than 600 patients in the Russian Federation are already receiving this drug.
Alexander Lila, Corresponding Member of the Russian Academy of Sciences

The drug is prescribed to patients who have not undergone treatment using genetic engineering therapy. Currently, four medical centers in Moscow, St. Petersburg and Novosibirsk are conducting such therapy in hospitals.

The drug is administered intravenously via a drip. The second infusion — drug administration — is carried out three months after the first, and then every six months. Treatment can continue for several years, but patients can lead a full life.

Bekhterev's disease — is a chronic disease of the spine and joints. Its main symptoms are: lower back pain, which worsens at night and in the morning, and stiffness of movements. Most often, the disease affects young men, the exact cause of the disease is unknown, a key role is played by genetic predisposition.

Read more materials on the topic:



Источники
TASS

Now on home